Ppapdc1a Inhibitors
Ppapdc1a inhibitors are a class of chemical compounds that specifically inhibit the activity of the enzyme Phosphatidic Acid Phosphatase Domain Containing 1A (PPAPDC1A). This enzyme belongs to the lipid phosphate phosphatase (LPP) family, which is involved in the regulation of bioactive lipid intermediates, such as phosphatidic acid and lysophosphatidic acid. The PPAPDC1A enzyme plays a key role in the dephosphorylation of phosphatidic acid, a crucial lipid signaling molecule that participates in a variety of intracellular processes, including membrane synthesis, lipid metabolism, and cellular signaling pathways. The inhibition of PPAPDC1A by specific inhibitors can affect the delicate balance of lipid intermediates, thereby modulating multiple signaling cascades that depend on these lipid species.
The chemical design of Ppapdc1a inhibitors typically involves the use of structural analogs that can bind competitively or allosterically to the enzyme's active site, thereby preventing it from catalyzing the dephosphorylation reaction. These inhibitors may contain hydrophobic domains that allow them to interact with the lipid-binding regions of the enzyme, as well as polar groups that can form hydrogen bonds with catalytic residues. Their efficacy as enzyme inhibitors can be characterized by their selectivity, potency, and binding affinity. Additionally, various structure-activity relationship (SAR) studies may guide the optimization of Ppapdc1a inhibitors by modifying specific functional groups to enhance their specificity for the PPAPDC1A enzyme without affecting other members of the lipid phosphate phosphatase family. Understanding the chemical nature of these inhibitors offers valuable insights into lipid metabolism and the broader regulatory mechanisms within the cell membrane environment.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of phosphoinositide 3-kinase (PI3K), a key enzyme involved in cell signaling. Inhibition of PI3K by Wortmannin may lead to the downregulation of PLPP4 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks), which are involved in various cellular processes. Inhibition of PI3K by LY294002 may result in the inhibition of PLPP4 expression. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective β-adrenergic receptor antagonist. It has been suggested that β-adrenergic signaling can regulate PLPP4 expression. Inhibition of β-adrenergic receptors by Propranolol may impact PLPP4 expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), an upstream kinase of ERK1/2. Inhibition of MEK/ERK signaling by U0126 may lead to the downregulation of PLPP4 expression. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of Raf-1 kinase, a component of the ERK signaling pathway. Inhibition of Raf-1 kinase by GW5074 may lead to the inhibition of the ERK pathway, potentially downregulating PLPP4 expression. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $336.00 $1642.00 | 20 | |
Calphostin C is a potent and specific inhibitor of protein kinase C (PKC). Inhibition of PKC by Calphostin C may impact downstream signaling pathways, potentially influencing the expression of PLPP4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB202190 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase by SB202190 may lead to the downregulation of PLPP4 expression, as p38 MAP kinase signaling is involved in the regulation of various cellular processes. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase by SB203580 may result in the downregulation of PLPP4 expression, as p38 MAP kinase signaling is involved in the regulation of various cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK1). Inhibition of MEK1 by PD98059 may lead to the downregulation of the ERK pathway, potentially impacting the expression of PLPP4. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of protein kinase C (PKC). Inhibition of PKC by Bisindolylmaleimide I may influence downstream signaling pathways, potentially impacting the expression of PLPP4. | ||||||